Equities Analysts Issue Forecasts for DYN Q1 Earnings

Dyne Therapeutics, Inc. (NASDAQ:DYN) – HC Wainwright issued their Q1 2026 EPS estimates for shares of Dyne Therapeutics in a research note issued to investors on Tuesday, March 3rd. HC Wainwright analyst A. Ghosh forecasts that the company will earn ($0.76) per share for the quarter. HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Dyne Therapeutics’ current full-year earnings is ($3.44) per share. HC Wainwright also issued estimates for Dyne Therapeutics’ Q2 2026 earnings at ($0.76) EPS and Q3 2026 earnings at ($0.76) EPS.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Monday, March 2nd. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02).

Several other equities research analysts have also issued reports on the company. TD Cowen reiterated a “buy” rating on shares of Dyne Therapeutics in a report on Monday, December 8th. Evercore reduced their target price on shares of Dyne Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a research note on Monday, December 15th. Robert W. Baird set a $30.00 target price on shares of Dyne Therapeutics in a research report on Monday, December 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Wednesday, January 21st. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating for the company in a report on Tuesday, January 20th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.00.

Dyne Therapeutics Price Performance

DYN opened at $15.20 on Thursday. The stock has a fifty day moving average price of $17.15 and a 200 day moving average price of $17.03. The company has a current ratio of 22.25, a quick ratio of 13.47 and a debt-to-equity ratio of 0.15. Dyne Therapeutics has a 1 year low of $6.36 and a 1 year high of $25.00. The stock has a market cap of $2.51 billion, a price-to-earnings ratio of -4.29 and a beta of 1.34.

Institutional Investors Weigh In On Dyne Therapeutics

A number of hedge funds have recently made changes to their positions in DYN. Seven Fleet Capital Management LP bought a new position in Dyne Therapeutics during the 4th quarter valued at about $1,373,000. T. Rowe Price Investment Management Inc. grew its stake in Dyne Therapeutics by 523.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock worth $343,085,000 after buying an additional 14,727,667 shares during the last quarter. Invesco Ltd. increased its holdings in shares of Dyne Therapeutics by 17.1% during the fourth quarter. Invesco Ltd. now owns 137,684 shares of the company’s stock worth $2,693,000 after buying an additional 20,121 shares in the last quarter. Axxcess Wealth Management LLC acquired a new stake in shares of Dyne Therapeutics during the fourth quarter worth approximately $2,226,000. Finally, XTX Topco Ltd raised its stake in shares of Dyne Therapeutics by 93.9% in the fourth quarter. XTX Topco Ltd now owns 56,661 shares of the company’s stock valued at $1,108,000 after acquiring an additional 27,446 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics News Roundup

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and maintained a $50 price target while publishing quarter-by-quarter EPS forecasts that are in line with management’s cadence — this is supportive for longer‑term sentiment. HC Wainwright reiterates Buy, $50 PT
• Positive Sentiment: Lifesci Capital nudged up its Q1 and Q3 2026 EPS forecasts slightly (Q1: from -$0.77 to -$0.76; Q3: from -$0.85 to -$0.83), signaling modestly improved near-term expectations from that shop. Lifesci raises Q1 & Q3 forecasts
• Neutral Sentiment: Reported short interest data for early March is effectively zero/indeterminate (entry shows 0 shares and NaN change), so short-covering or large new shorts are not a current driver based on that release.
• Neutral Sentiment: Several small, offsetting analyst estimate moves from Lifesci Capital (Q2 and Q4 nudged slightly lower while other quarters nudged higher) leave the consensus full‑year loss estimate unchanged at roughly -$3.44, implying no material change to the broad street view. Lifesci mixed estimate revisions
• Negative Sentiment: Investors reacted to the company’s latest quarterly result, which missed EPS expectations (reported -$0.76 vs. consensus -$0.74), prompting an immediate negative move in the stock. Stock down after disappointing earnings
• Negative Sentiment: Lifesci Capital lowered its Q4 2026 EPS forecast slightly (from -$0.85 to -$0.86) and trimmed other quarter forecasts overall, reflecting modest downward revisions to near‑term profitability expectations. Lifesci lowers Q4 forecast

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.